申请人:Mochida Pharmaceutical Co., Ltd.
公开号:EP2518064A1
公开(公告)日:2012-10-31
There is a need for FAAH inhibitors capable of oral administration and having excellent efficacy, particularly agents for the prevention and treatment of pain. Disclosed are novel arylurea compounds represented by formula (I), salts or solvates thereof, and pharmaceutical compositions comprising the same as an active ingredient. The pharmaceutical composition is used primarily for FAAH inhibitors, or agents for prevention and treatment of pain.
需要具有口服能力且具有出色疗效的FAAH抑制剂,特别是用于预防和治疗疼痛的药物。揭示了由式(I)表示的新型芳基脲类化合物,其盐或溶剂,以及包含其作为活性成分的药物组合物。该药物组合物主要用于FAAH抑制剂,或用于预防和治疗疼痛的药物。